A Randomised Phase II Trial to Evaluate the Feasibility of Radiotherapy Dose Escalation, Facilitated by Intensity-Modulated Arc Radiotherapy Techniques, in High-Risk Neuroblastoma *

被引:0
作者
Gains, J. E. [1 ]
Patel, A. [2 ]
Chang, Yen-Ching [1 ]
Mandeville, H. C. [3 ]
Smyth, G. [4 ]
Stacey, C. [5 ]
Talbot, J. [3 ]
Wheatley, K. [2 ]
Gaze, M. N. [1 ]
机构
[1] Univ Coll London Hosp NHS Fdn Trust, Dept Oncol, 250 Euston Rd, London NW1 2PG, England
[2] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, England
[3] Royal Marsden NHS Fdn Trust, Dept Radiotherapy, Sutton, England
[4] Royal Marsden NHS Fdn Trust, Natl Radiotherapy Trials Qual Assurance Grp, Sutton, England
[5] Univ Coll London Hosp NHS Fdn Trust, Radiotherapy Phys Grp, London, England
关键词
Dose escalation; intensity-modulated arc therapy; neuroblastoma; organs at risk; radiotherapy; randomised trial; BEAM-RADIATION-THERAPY; IMPROVES; SYSTEM;
D O I
10.1016/j.clon.2024.03.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND AND PURPOSE: For high-risk neuroblastoma, planning target volume coverage is often compromised to respect adjacent kidney tolerance. This trial investigated whether intensity-modulated arc radiotherapy techniques (IMAT) could facilitate dose escalation better than conventional techniques. MATERIALS AND METHODS: Children with high-risk abdominal neuroblastoma referred for radiotherapy to the primary tumour site and involved regional lymph nodes were randomised to receive either standard dose (21 Gy in 14 fractions) or escalated dose (36 Gy in 24 fractions) radiotherapy. Dual planning with both a conventional anterior-posterior parallel opposed pair radiotherapy technique and an IMAT technique was performed. The quality of target volume and organ-at-risk delineation, and dosimetric plans, were externally reviewed. Dosimetric parameters were used to judge the superior technique for treatment. This feasibility trial was not powered to detect improvement in outcome with dose escalation. RESULTS: Between 2017 and 2020, 50 patients were randomised and dual-planned. The IMAT technique was judged more favourable in 48 patients. In all patients randomised to receive 36 Gy, IMAT would have permitted delivery of the full dose (median D50% 36.0 Gy, inter-quartile range 36.0-36.1 Gy) to the target volume, whereas dose compromise would have been required with conventional planning (median D50% 35.6 Gy, inter-quartile range 28.7-35.9 Gy). CONCLUSION: IMAT facilitates safe dose escalation to 36 Gy in patients receiving radiotherapy for neuroblastoma. The value of dose escalation is now being evaluated in a current prospective phase III randomised trial. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:e154 / e162
页数:9
相关论文
共 28 条
  • [1] [Anonymous], 2012, ICRU Report 83
  • [2] [Anonymous], COMMON TERMINOLOGY C
  • [3] The Evidence for External Beam Radiotherapy in High-Risk Neuroblastoma of Childhood: A Systematic Review
    Arumugam, S.
    Manning-Cork, N. J.
    Gains, J. E.
    Boterberg, T.
    Gaze, M. N.
    [J]. CLINICAL ONCOLOGY, 2019, 31 (03) : 182 - 190
  • [4] Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study
    Braunstein, Steve E.
    London, Wendy B.
    Kreissman, Susan G.
    Villablanca, Judith G.
    Davidoff, Andrew M.
    DeSantes, Kenneth
    Castleberry, Robert P.
    Murray, Kevin
    Diller, Lisa
    Matthay, Katherine
    Cohn, Susan L.
    Shulkin, Barry
    von Allmen, Daniel
    Parisi, Marguerite T.
    Van Ryn, Collin
    Park, Julie R.
    La Quaglia, Michael P.
    Haas-Kogan, Daphne A.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
  • [5] Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial
    Casey, Dana L.
    Kushner, Brian H.
    Cheung, Nai-Kong, V
    Modak, Shakeel
    Basu, Ellen M.
    Roberts, Stephen S.
    LaQuaglia, Michael P.
    Wolden, Suzanne L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (02): : 409 - 414
  • [6] RADIOTHERAPY IMPROVES THE OUTLOOK FOR PATIENTS OLDER THAN 1 YEAR WITH PEDIATRIC ONCOLOGY GROUP STAGE-C NEUROBLASTOMA
    CASTLEBERRY, RP
    KUN, LE
    SHUSTER, JJ
    ALTSHULER, G
    SMITH, IE
    NITSCHKE, R
    WHARAM, M
    MCWILLIAMS, N
    JOSHI, V
    HAYES, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (05) : 789 - 795
  • [7] The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
    Cohn, Susan L.
    Pearson, Andrew D. J.
    London, Wendy B.
    Monclair, Tom
    Ambros, Peter F.
    Brodeur, Garrett M.
    Faldum, Andreas
    Hero, Barbara
    Iehara, Tomoko
    Machin, David
    Mosseri, Veronique
    Simon, Thorsten
    Garaventa, Alberto
    Castel, Victoria
    Matthay, Katherine K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 289 - 297
  • [8] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC)
    COX, JD
    STETZ, J
    PAJAK, TF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05): : 1341 - 1346
  • [9] Gains JE, 2013, FUTURE ONCOL, V9, P439, DOI [10.2217/FON.12.199, 10.2217/fon.12.199]
  • [10] Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
    Garaventa, Alberto
    Poetschger, Ulrike
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Elliott, Martin
    Ash, Shifra
    Chan, Godfrey C. F.
    Laureys, Genevieve
    Beck-Popovic, Maja
    Vettenranta, Kim
    Balwierz, Walentyna
    Schroeder, Henrik
    Owens, Cormac
    Cesen, Maja
    Papadakis, Vassilios
    Trahair, Toby
    Schleiermacher, Gudrun
    Ambros, Peter
    Sorrentino, Stefania
    Pearson, Andrew D. J.
    Ladenstein, Ruth Lydia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (23) : 2552 - +